ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Elevai Labs Inc

Elevai Labs Inc (ELAB)

0,0289
-0,0301
(-51,02%)
Geschlossen 03 November 10:00PM
0,029
0,0001
(0,35%)
Nach Börsenschluss: 12:59AM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,029
Gebot
0,0283
Fragen
0,035
Volumen
202.280.835
0,0283 Tagesbereich 0,0399
0,027 52-Wochen-Bereich 4,2442
Marktkapitalisierung
Handelsende
0,059
Handelsbeginn
0,0386
Letzter Handelszeitpunkt
Finanzvolumen
US$ 6.552.746
VWAP
0,032394
Durchschnittliches Volumen (3 Mio.)
26.237.482
Ausgegebene Aktien
20.192.114
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,14
Gewinn pro Aktie (EPS)
-0,21
Erlöse
1,71M
Nettogewinn
-4,3M

Über Elevai Labs Inc

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed... Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Elevai Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELAB. The last closing price for Elevai Labs was US$0,06. Over the last year, Elevai Labs shares have traded in a share price range of US$ 0,027 to US$ 4,2442.

Elevai Labs currently has 20.192.114 shares in issue. The market capitalisation of Elevai Labs is US$1,19 million. Elevai Labs has a price to earnings ratio (PE ratio) of -0.14.

ELAB Neueste Nachrichten

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicinesThe Investigational...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.Elevai believes that EL-32 has the...

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an...

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.1347-82.28466707390.16370.1840.0271004764780.09639005CS
4-0.0767-72.56385998110.10570.1840.027368139940.09762088CS
12-0.3121-91.49809440050.34110.390.027262374820.1280022CS
26-0.6594-95.7873329460.68840.760.027122669790.13115188CS
52-3.971-99.27544.24420.02770029460.19672721CS
156-3.971-99.27544.24420.02770029460.19672721CS
260-3.971-99.27544.24420.02770029460.19672721CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
VSTEVast Renewable Ltd
US$ 4,98
(149,00%)
68,54M
INVZWInnoviz Technologies Ltd
US$ 0,096
(96,71%)
22,71k
CDXCChromaDex Corporation
US$ 5,87
(68,19%)
37,88M
ATHAAthira Pharma Inc
US$ 0,606
(41,56%)
239,63M
TILEInterface Inc
US$ 23,24
(33,03%)
2,16M
EPIXESSA Pharma Inc
US$ 1,45
(-72,12%)
34,3M
ELABElevai Labs Inc
US$ 0,0288
(-51,19%)
202,28M
OSTOstin Technology Group Company Ltd
US$ 0,275
(-45,00%)
2,27M
LXRXLexicon Pharmaceuticals Inc
US$ 1,23
(-36,92%)
21M
VCIGVCI Global Ltd
US$ 0,0583
(-27,58%)
26,57M
ATHAAthira Pharma Inc
US$ 0,606
(41,56%)
236,07M
SQQQProShares UltraPro Short QQQ
US$ 7,44
(-2,11%)
214,96M
NVDANVIDIA Corporation
US$ 135,40
(1,99%)
206,38M
ELABElevai Labs Inc
US$ 0,0288
(-51,19%)
201,61M
INTCIntel Corporation
US$ 23,20
(7,81%)
171,4M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock